Simcere Zaiming Licenses Tri-Specific Antibody SIM0660 to Roche in Deal Worth Up to $1.53 Billion
核心洞察
Simcere Zaiming (搜索) granted Roche exclusive global rights to develop, manufacture, and commercialize SIM0660 (搜索), a tri-specific antibody targeting CD79a (搜索), CD19 (搜索), and CD3 (搜索).
Simcere Zaiming (搜索) is eligible to receive up to $1.53 billion in total payments, including a $75 million upfront payment, plus tiered royalties of up to double digits on net sales.
SIM0660 (搜索) uses a dual-targeting approach to CD79a (搜索) and CD19 (搜索) to induce T cell-mediated cytotoxicity while limiting cytokine release, offering potential benefit for patients previously treated with CD20- or CD19-directed therapies.
Simcere Zaiming (搜索), an oncology-focused subsidiary of Simcere Pharmaceutical Group (搜索) (2096.HK), has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660 (搜索), a tri-specific antibody targeting CD79a (搜索), CD19 (搜索), and CD3 (搜索) with therapeutic potential across B-cell-mediated diseases. Under the terms of the agreement, Roche will acquire exclusive worldwide rights to develop, manufacture, and commercialize SIM0660, while Simcere Zaiming is eligible to receive up to $1.530 billion in total payments, including $75 million upfront, along with tiered royalties of up to double digits on future net sales.
A First-in-Class Dual-Targeting T-Cell Engager
SIM0660 (搜索) is a tri-specific antibody developed by Simcere Zaiming (搜索) using its proprietary T-cell engager poly-specific antibody technology. The molecule combines a CD3 (搜索)-engaging arm with binding domains targeting the two B-cell antigens CD79a (搜索) and CD19 (搜索) to induce potent T cell-mediated cytotoxicity while limiting cytokine release.
With its potential first-in-class dual-targeting approach to CD79a (搜索) and CD19 (搜索), SIM0660 (搜索) is designed to provide broad coverage across B-cell-mediated diseases. The therapy may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit.
Strategic Rationale and Executive Perspectives
"Simcere Zaiming (搜索) is committed to develop highly innovative T-cell engagers through our proprietary TCE platform," said Renhong Tang, Chairman and CEO of Simcere Zaiming. "We are pleased to collaborate with Roche to accelerate the clinical development of SIM0660 (搜索). Through our synergistic innovation, we hope to benefit global patients soon."
"This agreement with Simcere Zaiming (搜索) reflects our commitment to partnering with innovative companies to advance and deliver new therapeutic options for patients in need. SIM0660 (搜索) represents a potential advancement for patients with B-cell-mediated diseases," said Boris L. Zaïtra, Head of Corporate Business Development at Roche.
A Growing Out-Licensing Portfolio
To date, Simcere Pharmaceutical Group (搜索) has completed six out-licensing transactions, with a potential aggregate total consideration exceeding US$6.1 billion. Simcere Zaiming (搜索) has successfully launched several innovative products in China, including Enzeshu, COSELA, Enweida, Endostar, and Enlituo, and is focused on delivering potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.